Boccia Ralph, Cooper Nichola, Ghanima Waleed, Boxer Michael A, Hill Quentin A, Sholzberg Michelle, Tarantino Michael D, Todd Leslie K, Tong Sandra, Bussel James B
Centre for Cancer and Blood Disorders, Bethesda, MD, USA.
Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
Br J Haematol. 2020 Sep;190(6):933-938. doi: 10.1111/bjh.16959. Epub 2020 Jul 23.
Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second-line therapy (after steroids ± immunoglobulins) versus third-or-later-line therapy (after ≥2 prior lines of therapy including a second-line agent). Platelet responses ≥50 000/µl were observed in 25/32 (78%) second-line and 54/113 (48%) third-or-later-line patients. Bleeding events were less frequent in second-line (28%) versus third-or-later-line (45%) patients. Responses once achieved tended to be durable in both groups. The safety profile was similar in both groups. In this post hoc analysis, fostamatinib was more effective as second-line than third-or-later-line therapy for ITP.
福斯他替尼在成人免疫性血小板减少症（ITP）的3期试验中显示出疗效。事后分析比较了接受福斯他替尼作为二线治疗（在使用类固醇±免疫球蛋白之后）的患者与三线或更后线治疗（在≥2线先前治疗包括二线药物之后）的患者。在25/32（78%）的二线患者和54/113（48%）的三线或更后线患者中观察到血小板反应≥50000/µl。二线患者（28%）的出血事件比三线或更后线患者（45%）更少。两组一旦达到反应往往都具有持久性。两组的安全性概况相似。在这项事后分析中，对于ITP，福斯他替尼作为二线治疗比三线或更后线治疗更有效。
